Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
Cells present in adipose tissue are used to stroke and stroke related diseases and disorders in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
1 . A method for treating stroke in a patient, comprising administering to the patient a concentration of regenerative cells.
2 . The method of claim 1 , wherein the subject is human.
3 . The method of claim 1 , wherein the regenerative cells are comprised of stem cells.
4 . The method of claim 1 , wherein the regenerative cells are comprised of progenitor cells.
5 . The method of claim 1 , wherein the regenerative cells are comprised of a combination of stem cells and progenitor cells.
6 . The method of claim 1 , wherein the stroke is selected from ischemic stroke and hemorrhagic stroke.
7 . The method of claim 1 , wherein the stroke is treated by increasing blood flow to the regions of ischemia.
8 . The method of claim 1 , wherein the stroke is treated by producing functional neurons.
9 . The method of claim 1 , wherein the stroke is treated by recruiting endogenous neural stem cells to the regions of ischemia.
10 . The method of claim 1 , wherein the stroke is treated by producing microglial cells.
11 . The method of claim 1 , wherein the method comprises administering a bolus of the regenerative cells.
12 . The method of claim 1 , wherein the method comprises administering multiple doses of the regenerative cells.
13 . The method of claim 1 , wherein the method further comprises administering one or more angiogenic factors.
14 . The method of claim 1 , wherein the method further comprises administering one or more neurogenic factors.
15 . The method of claim 1 , wherein the method further comprises administering one or more growth factors selected from bFGF, HGF, IL-6 and IL-13.
16 . The method of claim 1 , wherein the wherein the method further comprises administering one or more immunosuppressive drugs.
17 . The method of claim 1 , wherein the regenerative cells are administered via a subcutaneous, intra-carotid artery, intra-arterial, intra-thecal or intro-parenchymal delivery routes.
18 . The method of claim 1 , wherein the method further comprises administering the regenerative cells to the patient's cerebral parenchyma.
19 . The method of claim 1 , wherein the regenerative cells are grown in cell culture prior to being administered to the patient.
20 . The method of claim 19 , wherein the regenerative cells are grown in culture conditions that promote differentiation towards a neuronal phenotype.
21 . The method of claim 19 , wherein the cell culture conditions promote differentiation towards an angiogenic phenotype.
22 . The method of claim 1 , wherein the regenerative cells are modified by gene transfer such that expression of one or more genes in the modified regenerative cells is altered.
23 . The method of claim 22 , wherein the modification results in alteration of the level of angiogenesis in the subject.
24 . The method of claim 22 , wherein the modification results in alteration of the level of bFGF, HGF, IL-6 and IL-13, or any combinations thereof.
25 . The method of claim 22 , wherein the modification results in alteration of the homing properties of the regenerative cells.